Revelation Biosciences Reports Positive Clinical Data for Gemini

Revelation Biosciences, Inc. has announced successful top-line data from its Phase 1b PRIME study involving Gemini, their innovative treatment for chronic kidney disease (CKD). This clinical-stage company held a webcast to discuss these promising results for patients in stages 3 and 4 CKD. Gemini significantly lowered inflammatory activity and restored normal cellular responses, marking a potential breakthrough in treating inflammation.

The study included 40 patients across various US clinics. The drug was well-tolerated, showing only mild adverse effects at target doses. Notably, for patients with high background inflammation, Gemini reduced inflammation to healthy levels and improved immune response. Revelation Biosciences plans to present further results as they progress towards regulatory discussions with the FDA later this year.

The webcast provided additional insights, and the company is eager to advance Gemini's development as a potential therapy for CKD. More detailed data analysis is ongoing to explore further implications.